Conformational-Analysis-Guided Discovery of 2,3-Disubstituted Pyridine IDO1 Inhibitors
作者:Emily C. Cherney、Liping Zhang、Weiwei Guo、Audris Huang、David Williams、Steven Seitz、Weifang Shan、Xiao Zhu、Johnni Gullo-Brown、Derrick Maley、Tai-an Lin、John T. Hunt、Christine Huang、Zheng Yang、Celia J. D’Arienzo、Lorell N. Discenza、Asoka Ranasinghe、Mary F. Grubb、Sarah C. Traeger、Xin Li、Kathy A. Johnston、Lisa Kopcho、Mark Fereshteh、Kimberly A. Foster、Kevin Stefanski、Diane Delpy、Gopal Dhar、Aravind Anandam、Sandeep Mahankali、Shweta Padmanabhan、Prabhakar Rajanna、Venkata Murali、T. Thanga Mariappan、Shabeerali Pattasseri、Roshan Y. Nimje、Zhenqiu Hong、James Kempson、Richard Rampulla、Arvind Mathur、Anuradha Gupta、Robert Borzilleri、Gregory Vite、Aaron Balog
DOI:10.1021/acsmedchemlett.1c00236
日期:2021.7.8
with an alternative aromatic system led to the discovery of 2,3-disubstituted pyridines as suitable replacements. Further optimization, which included lowering ClogP in combination with strategic fluorine incorporation, led to the discovery of compound 29, a potent, selective IDO1 inhibitor with robust pharmacodynamic activity in a mouse xenograft model.
IDO1 抑制剂已显示出作为免疫疗法治疗多种癌症的前景,包括转移性黑色素瘤和肾细胞癌。我们最近报道了几种新型血红素置换 IDO1 抑制剂的鉴定,包括临床分子 linrodostat (BMS-986205) 和 BMS-986242。这两种分子都含有喹啉,虽然它们存在于成功的药物中,但已知它们可能对氧化代谢敏感。将这种喹啉与另一种芳族系统交换的努力导致发现 2,3-二取代吡啶作为合适的替代品。进一步优化,包括降低 ClogP 并结合战略性氟掺入,导致化合物29的发现,一种有效的、选择性的 IDO1 抑制剂,在小鼠异种移植模型中具有强大的药效学活性。